This trial is active, not recruiting.

Condition non-small cell lung cancer
Treatment pd0332991
Phase phase 2
Target CDK4
Sponsor University of Florida
Start date February 2011
End date February 2014
Trial size 19 participants
Trial identifier NCT01291017, PD0332991


The purpose of this study is to determine the efficacy and the toxicities of the study drug PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype retinoblastoma protein (RB) and inactivated cyclin dependent kinase (CDK) N2A in the tumor.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
PD0332991 125 mg PO days 1 - 21
PD0332991 125 mg PO days 1 - 21

Primary Outcomes

Tumor response by direct RECIST measurement
time frame: 6 months

Secondary Outcomes

Overall Survival
time frame: 14 months
Progression-free survival
time frame: 12 months
Type of study drug toxicities based on adverse events
time frame: 24 months
Plasma levels
time frame: 6 months
Grade of study drug toxicity
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically or cytologically proven non small cell lung cancer - Stage IV (M1a or M1b) disease. Patients may also have recurrence of early-stage disease or locally advanced disease with the presence of new distant metastases. - Cyclin dependent kinase (CDK)N2a (p16) protein absent or expressed at a low level in tumor biopsy specimen - Failed or intolerant of at least one prior systemic chemotherapy regimen (there is no maximum number of prior chemotherapy regimens) - Eastern cooperative oncology group (ECOG) performance status 0-2 - Age >18 years. - Adequate organ and bone marrow function - Measurable disease by standard RECIST v1.1 criteria - Life expectancy of greater than 3 months Exclusion Criteria: - Inability to understand or sign the informed consent document - Inability or unwillingness to take oral medications - No available tissue specimen for p16 analysis - Chemotherapy or radiotherapy within 3 weeks prior to beginning the study drug - Other investigational agents within 4 weeks prior to beginning the study drug - All side effects from previous chemotherapy, radiotherapy or investigational agents not resolved, returned to baseline or returned to Grade 1 toxicity (exceptions are grade 2 alopecia and grade 2 peripheral neuropathy) - Major surgery within 4 weeks prior to beginning the study drug - Surgical scar from previous surgery not healed prior to beginning the study drug - High-dose or chronic steroid use - High-dose statins within 7 days - History of rhabdomyolysis - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, stroke or myocardial infarction within 3 months, or psychiatric illness/social situations that would limit compliance with study requirements. - Baseline corrected QT interval (QTc) >470ms - Pre-existing clinically significant cardiac, hepatic or renal dysfunction at the discretion of the treating physician - Untreated or uncontrolled (symptomatic or asymptomatic) brain metastases - Leptomeningeal carcinomatosis - Inability or unwillingness to use contraception during the treatment period by patients with reproductive potential. - Pregnant or breastfeeding women - HIV-positive patients on combination antiretroviral therapy

Additional Information

Official title A Phase II Clinical Trail of the Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Previously Treated, Advanced NSCLC Patients With Wildtype Retinoblastoma Protein (RB) and Inactive Cyclin Dependent Kinase (CDK)N2a
Principal investigator Priya Gopalan, MD, PhD
Description The oral drug PD0332991 is a highly selective reversible inhibitor of cyclin-dependent kinases 4 & 6 that is being studied for use in the treatment of advanced non-small cell lung cancer.
Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by University of Florida.